FAQ: Annovis Bio Appoints Mark Guerin as CFO and Company Overview

What is the main announcement in this content?

Annovis Bio Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as its new Chief Financial Officer to help guide the company as its lead drug candidate, buntanetap, advances through late-stage trials for neurodegenerative diseases.

Who is Mark Guerin and what is his background?

Mark Guerin is a certified professional accountant with CPA, CMA, and CFM credentials who previously served as CFO of Onconova Therapeutics (now Traws Pharma), where he oversaw multiple financings and a merger. His earlier roles include senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand.

Why is this appointment significant for Annovis Bio?

This appointment brings significant financial expertise to Annovis Bio as the company advances buntanetap through late-stage clinical trials, with Guerin’s experience in financings and mergers being particularly valuable for guiding the company through this critical development phase.

What is Annovis Bio’s lead drug candidate and what diseases does it target?

Annovis Bio’s lead drug candidate is buntanetap, which is being developed to treat neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD), with the company working to replicate its early success in registrational studies.

Where is Annovis Bio headquartered and what is their mission?

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s disease, with a commitment to developing innovative therapies that improve patient outcomes and quality of life.

How can I learn more about Annovis Bio and follow their updates?

You can visit their website at www.annovisbio.com, follow them on LinkedIn, YouTube, and X, or access the latest news and updates relating to ANVS in the company’s newsroom at https://ibn.fm/ANVS.

What is BioMedWire and what role does it play in this content?

BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences developments, and it is one of 70+ brands within IBN’s Dynamic Brand Portfolio that distributes this type of corporate news through various channels including wire services and social media.

Where can I view the full press release about this appointment?

The full press release can be viewed at https://ibn.fm/AmfSU, which provides complete details about Mark Guerin’s appointment as CFO of Annovis Bio.